Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 397

Sort by

Sort Order Select

Journal Articles

sBCMA and MTV prediction of outcome for CART

Hermann Einsele, K. Martin Kortüm

Blood (2025) 145 (15): 1594–1595.

https://doi.org/10.1182/blood.2024027446

Published: 2025

Journal Articles

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Blood (2024) 144 (20): 2121–2135.

https://doi.org/10.1182/blood.2024024590

Published: 2024

Includes: Supplemental data

Journal Articles

Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia

Jennifer Wing Lam Cheung, Prachurjya Panda, Xiang Zhou, Katrin Sinning, Ankit Agrawal, Andy Shing Fung Chan, Johannes Duell, Johannes Waldschmidt, Hermann Einsele, Martin Väth, Andreas Rosenwald, Dominic Grün, Leo Rasche

Blood (2024) 144 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2024-203052

Published: 2024

Journal Articles

Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

Ajay K. Nooka, Hira Mian, Cindy Lee, Paula Rodríguez-Otero, Shaji Kumar, Hermann Einsele, Deeksha Vishwamitra, Diego Vieyra, Colleen Kane, Michele Kosh, Tara J Masterson, Christoph Heuck, Ankit Kansagra, Philippe Moreau

Blood (2024) 144 (Supplement 1): 4757.1.

https://doi.org/10.1182/blood-2024-199752

Published: 2024

Journal Articles

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Elena Zamagni, Tobias Silzle, Ivan Špička, Sabrin Tahri, Sarah Lonergan, Inger S. Nijhof, Antonietta Pia Falcone, Evangelos Terpos, Jakub Radocha, Roberto Mina, Guldane Cengiz Seval, Meral Beksac, Cesar Rodriguez, Marcelo C. Pasquini, Michel Delforge, Vania Hungria, Donna Reece, Philippe Moreau, Yael C. Cohen, Kihyun Kim, Dominik Dytfeld, Jiří Minařík, Irene Strassl, Jelena Bila, Martin Schreder, Janusz Krawczyk, Fredrik Schjesvold, Caroline Cicin-Sain, Christoph Driessen, Gordon Cook, Lugui Qiu, Gonzalo Martin Garate, Agoston Gyula Szabo, Roman Hájek, Marc S. Raab, Silvia Mangiacavalli, Hermann Einsele, Andrew Spencer, Mario Boccadoro, Helen Vassalou, Lixia Pei, Yingqi Shi, Maria Krevvata, Ryan Gruber, Caline Sakabedoyan, Margaret Cobb, Jagoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels W.C.J. van de Donk

Blood (2024) 144 (Supplement 1): 494.

https://doi.org/10.1182/blood-2024-205608

Published: 2024

Journal Articles

Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Blood (2024) 144 (Supplement 1): 493.

https://doi.org/10.1182/blood-2024-206003

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation Promotes Atherosclerosis in Mice Driven By Donor CD8+ T Cells

Haroon Shaikh, Ivana Jorgacevic, Hla Ali, Maja Bundalo, Sarah Schäfer, Michael AG Kern, Maike Büttner- Herold, Clément Cochain, Antoine-Emmanuel Saliba, Giuseppe Rizzo, Juan Vargas, Louis Boon, Wolfgang Herr, Hermann Einsele, Friederike Berberich-Siebelt, Andreas Rosenwald, Andreas Beilhack, Alma Zernecke

Blood (2024) 144 (Supplement 1): 3402.

https://doi.org/10.1182/blood-2024-194190

Published: 2024

Journal Articles

Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

Blood (2024) 144 (Supplement 1): 3792.4.

https://doi.org/10.1182/blood-2024-206735

Published: 2024

Journal Articles

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Jan-Niklas Eckardt, Marius Bill, Konstanze Döhner, Christian Rausch, Klaus H Metzeler, Karsten Spiekermann, Sebastian Stasik, Tim Sauer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. H. Brummendorf, Utz Krug, Bernhard Wörmann, Hermann Einsele, Wolfgang Hiddemann, Dennis Görlich, Maria Cristina Sauerland, Björn Steffen, Andreas Neubauer, Andreas Burchert, Kerstin Schaefer-Eckart, Wolfgang E. Berdel, Christoph Schliemann, Stefan W. Krause, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Lars Fransecky, Jan Braess, Johannes Schetelig, Jan Moritz Middeke, Lars Bullinger, Michael Heuser, Felicitas R Thol, Hubert Serve, Claudia D Baldus, Uwe Platzbecker, Carsten Mueller-Tidow, Barbora Weinbergerova, Jiri Mayer, Pierre-Yves Dumas, Sarah Bertoli, Eric Delabesse, Christian Récher, Arnaud Pigneux, Tobias Herold, Arnold Ganser, Hartmut Döhner, Martin Bornhäuser, Christian Thiede, Christoph Röllig

Blood (2024) 144 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2024-201945

Published: 2024

Journal Articles

Local Myeloid Network Resilience Determines Organ-Specific Acute GvHD Outcomes

Michael AG Kern, Rèmi Doucet Ladevèze, Haroon Shaikh, Mariachiara Aloisi, Muthita Khamwong, Juan Vargas, Shreeya Tavkari, Hermann Einsele, Mercedes Gomez de Agüero, Andreas Beilhack

Blood (2024) 144 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2024-203697

Published: 2024

Journal Articles

Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström's Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)

Blood (2024) 144 (Supplement 1): 3010.

https://doi.org/10.1182/blood-2024-197901

Published: 2024

Journal Articles

Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations

Anna Fleischer, Mohammad Barakat, Sofie-Katrin Kadel, Julia Mersi, Johannes Waldschmidt, Hermann Einsele, K. Martin Kortüm, Imad Maatouk, Leo Rasche

Blood (2024) 144 (Supplement 1): 284.

https://doi.org/10.1182/blood-2024-205037

Published: 2024

Journal Articles

Bi-Allelic GPRC5D Alterations Provide Proliferative Advantage in Presence of Talquetamab

Umair Munawar, Seungbin Han, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Patrick Eiring, Julia Weingart, Xiang Zhou, Markus Sauer, Hermann Einsele, Leo Rasche, Johannes Waldschmidt, K. Martin Kortüm

Blood (2024) 144 (Supplement 1): 593.

https://doi.org/10.1182/blood-2024-200593

Published: 2024

Journal Articles

GPRC5D Status Impacts CD38 Expression in Multiple Myeloma

Umair Munawar, Julia Weingart, Patrick Eiring, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Seungbin Han, Max J Steinhardt, Xiang Zhou, Markus Sauer, Hermann Einsele, Leo Rasche, Johannes Waldschmidt, K. Martin Kortüm

Blood (2024) 144 (Supplement 1): 3267.

https://doi.org/10.1182/blood-2024-204863

Published: 2024

Journal Articles

Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy

Blood (2024) 144 (Supplement 1): 4688.

https://doi.org/10.1182/blood-2024-210233

Published: 2024

Journal Articles

CD31 and JAM-a Expressing Circulating Tumor Plasma Cells As Prognostic Biomarkers for Multiple Myeloma Disease

Blood (2024) 144 (Supplement 1): 4665.

https://doi.org/10.1182/blood-2024-209831

Published: 2024

Journal Articles

The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma

Jan H. Frenking, Christine Riedhammer, David N. Sedloev, Valentine Landrin, Mirco Julian Friedrich, Niels Weinhold, Martin K. Kortüm, Carsten Müller-Tidow, Hermann Einsele, Sandra Sauer, Leo Rasche, Marc S. Raab

Blood (2024) 144 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2024-210021

Published: 2024

Journal Articles

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Blood (2024) 144 (Supplement 1): 4758.

https://doi.org/10.1182/blood-2024-201783

Published: 2024

Journal Articles

Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis

Blood (2024) 144 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2024-210451

Published: 2024

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Blood (2024) 144 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2024-201630

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

sBCMA and MTV prediction of outcome for CART

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Allogeneic Hematopoietic Cell Transplantation Promotes Atherosclerosis in Mice Driven By Donor CD8+ T Cells

Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Local Myeloid Network Resilience Determines Organ-Specific Acute GvHD Outcomes

Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström's Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)

Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations

Bi-Allelic GPRC5D Alterations Provide Proliferative Advantage in Presence of Talquetamab

GPRC5D Status Impacts CD38 Expression in Multiple Myeloma

Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy

CD31 and JAM-a Expressing Circulating Tumor Plasma Cells As Prognostic Biomarkers for Multiple Myeloma Disease

The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only